Stemline Therapeutics, Inc. (STML) was a big mover last session with its shares rising over 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the uptrend for the company as the stock has gained nearly 18% since Feb 12.
This biopharmaceutical company has seen no estimate revision in the last 60 days. However, the Zacks Consensus Estimate has moved higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if Friday’s price action can turn into more strength down the road.
Stemline Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Some better-ranked stocks in the same industry include Alexion Pharmaceuticals, Inc. (ALXN), Biogen Idec Inc. (BIIB) and Actelion Ltd. (ALIOF). While Alexion and Biogen sport a Zacks Rank #1 (Strong Buy), Actelion carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment